Top News

• Expanding Trodelvy into the first-line setting strengthens Gilead’s oncology franchise, which has been growing alongside its dominant HIV business.
• Investors are now watching an FDA decision expected by August 27 on a once-daily single-tablet HIV regimen combining its drugs bictegravir and lenacapavir for patients whose virus is already controlled.
• Earlier this month, Gilead raised its full-year 2026 product sales guidance to $30.1–$30.4 billion from the prior range of $30.0–$30.4 billion.

Shares of Gilead Sciences (GILD) garnered retail investor attention on Monday after the company announced a key European regulatory win for its cancer drug Trodelvy, ahead of a U.S. Food and Drug Administration (FDA) decision on its once-daily HIV regimen.

The stock closed up 0.42%. 

New European Approval Broadens Trodelvy’s Reach

The European Commission authorized Trodelvy combined with Merck’s (MRK) Keytruda for certain adults with previously untreated advanced or metastatic triple-negative breast cancer. This makes the pairing the first antibody-drug conjugate plus immunotherapy option approved for this first-line setting across the European Union, Norway, Iceland, and Liechtenstein.

The decision rests on a late-stage trial in which the combination cut the risk of disease progression or death by 35% compared with chemotherapy plus Keytruda. It follows an earlier European nod for Trodelvy alone in patients who cannot receive certain drugs, positioning the medicine as a core treatment option for virtually all eligible first-line patients.

Expanding Trodelvy into the first-line setting strengthens Gilead’s oncology franchise, which has been growing alongside its dominant HIV business.

Strong Earnings And Strategic Push

The news builds on solid second-quarter results reported earlier this month. Total revenue climbed 10% to $7.8 billion, driven by 12% growth in HIV sales to $5.7 billion and a 26% rise in Trodelvy revenue. Gilead also raised its full-year 2026 product sales guidance to $30.1–$30.4 billion from the prior range of $30.0–$30.4 billion.

In parallel, the company has moved aggressively to expand its pipeline. It completed the acquisition of Arcellx to gain full ownership of a promising cell therapy for multiple myeloma, acquired Tubulis for next-generation antibody-drug conjugate technology, and acquired Ouro Medicines to enter T-cell engager therapies for autoimmune diseases.

Near-Term Catalyst Ahead

Investors are now watching an FDA decision expected by August 27 on a once-daily single-tablet HIV regimen combining its drugs bictegravir and lenacapavir for patients whose virus is already controlled. Approval would add another convenient treatment option and extend Gilead’s leadership in HIV.

How Did Retail Traders React?

On Stocktwits, real sentiment around GILD stock improved from ‘bearish’ to ‘neutral’ over the past 24 hours, while message volume remained ‘high.’

A Stocktwits user recommended buying the stock at current levels.

According to data from Koyfin, 22 of the 29 analysts covering GILD stock rate it 'Buy' or higher, while seven rate it 'Hold.' The stock has a 12-month average price target of $157.41, representing a potential upside of about 7% from the stock’s last close.

GILD stock has risen about 20% year-to-date. 

For updates and corrections, email newsroom[at]stocktwits[dot]com.<